Despite extensive research, treating idiopathic pulmonary fibrosis (IPF) and managing therapy side effects remain challenging. Clinical trials for IPF face issues like accurate diagnosis, recruitment complexities, and endpoint limitations. Recent advances in AI for lung scan evaluation can enhance diagnosis and ongoing lung health monitoring, including cough and fibrosis.
Explore our white paper to learn more about:
- Leveraging strategic trial design and AI innovation to improve diagnostics
- The increasing role of AI in patient recruitment and endpoint selection
- Integrating patient-centric approaches using meaningful clinical endpoints
